Stocks rebounded last week, bouncing back from the worst week of the new year. The Nasdaq surged 4.3% for its fourth positive week in a row. Meanwhile, the S&P 500 and the Dow posted smaller gains, rebounding from declines the previous week. With only two trading sessions left in January, the Nasdaq was on track to record its strongest monthly result since July.
The week ahead will be eventful, with the FOMC’s policy meeting taking center stage. At its meeting ending on Wednesday, the U.S. Federal Reserve is expected to lift its benchmark interest rate again. In 2022, the Fed approved seven rate increases, including a half-point hike in December, down from its previous three-quarter-point increases. Market participants are also looking forward to earnings from some of the largest companies in the world, including big tech firms Apple, Amazon, Google, and Meta Platforms.
Software stocks were among the market’s biggest losers in 2022 amid drastic shifts in Fed policy. But amid signs of cooling inflation over the past few months, interest rate hikes have slowed. With inflation collapsing, it seems likely that interest rates will continue falling through 2023. If they do, it could be up, up, and away for software stocks, such as our first of three recommendations for the week ahead.
A company with 400 million ‘patents’
One company has quietly compiled more than 400 million official trade secrets.
Trade secrets are like patents in that they protect valuable and proprietary information…
But unlike patents, trade secrets take less time to register… and more importantly, they never expire.
Which is a huge advantage for this little-known company.
You see, this company is using these trade secrets to build the world’s largest “codebase,” which will bethe key to it becoming “America’s Next Big Monopoly.”
Not surprisingly, Wall Street is starting to take notice. And the smart money is already pouring in.
Tech investor Cathie Wood has invested over $80 million already, and Microsoft founder Bill Gates has invested as well.
Get the details here before this story hits the mainstream media.
The next-generation data storage market is predicted to grow by 8.5% to $81 billion by 2025. All-flash data storage hardware and software products developer Pure Storage (PSTG) has upward solid top and bottom-line results, a healthy balance sheet, and growing cash flow. PSTG investors benefit from its subscription-based model, which is now at over $1 billion in annual recurring revenue. With a growing customer base in a market with substantial long-term growth potential, investors may want to take a bullish stance on this company.
“Card-Sized” Battery Set to Blow Lid off the Electric Vehicle Industry
This tech company’s new EV battery is so small and light, experts predict it may spur 1,000% growth in EV sales. Watch this stock.
StoneCo Ltd. (STNE) provides back-office software, loans, and other financial services to small and medium-sized businesses with a focus on reinvesting the cash it generates to acquire or build new financial products for its customer base. Since early 2019, the company has grown the number of small and medium business clients by 3x, revenue by 2.3x, and net income by 2.2×. Stoneco stock lost 53% of its value in 2022 on rising interest rates and macroeconomic risks in Brazil. But base interest rates in Brazil seem to have peaked, and a potential decline in the second half of 2023 is expected as Brazil’s inflation normalizes, reducing the margin pressure from rising financial expenses.
Bezos, Musk, and Yellen Planning Behind the Scenes [$150 Trillion]
While most Americans were distracted by mainstream media headlines predicting a stock market crash…
PhD Investigative Journalist Nomi Prins found evidence that shows the elites are spending trillions of dollars to “transform” the economy.
Jeff Bezos and Elon Musk have pledged billions of dollars to make it happen…
And Treasury Secretary Janet Yellen is working with 131 countries, 234 cities, and 695 of the world’s biggest companies –including Bank of America, Nike, and Exxon Mobil –to overhaul everything about the American way of life.
Go here right now to see what it means for your family and your money
Drugmaker, Viatris’ (VTRS) is profitable and looking for more growth. The company is trimming its less-profitable operations, including its biosimilars, women’s health division, and over-the-counter drugs. In its place, it is adding an ophthalmology franchise through the $750 million acquisitions of Oyster Point Pharma and Famy Life Sciences. The deal is expected to close in the first quarter of 2023. Management expects the acquisition to generate at least $1 billion in sales by 2028.